The rationale behind PEN-Cool is that even though we have therapies which can open up the artery, but we see that, like intravenous thrombolysis or endovascular thrombectomy, but not every patient who has a reperfusion ends up having good, meaningful recovery. So, when you have a stroke, the artery is occluded, and so the core area is already infarcted, but there is a region around the core, which is the penumbra, which is still viable for recovery if intervened on timely...
The rationale behind PEN-Cool is that even though we have therapies which can open up the artery, but we see that, like intravenous thrombolysis or endovascular thrombectomy, but not every patient who has a reperfusion ends up having good, meaningful recovery. So, when you have a stroke, the artery is occluded, and so the core area is already infarcted, but there is a region around the core, which is the penumbra, which is still viable for recovery if intervened on timely. It is this region that we are most interested in. So, but despite intravenous thrombolysis and endovascular thrombectomy, sometimes this tissue is actively undergoing damage, and that is why not every reperfusion translates into meaningful functional recovery. So, the rationale behind PEN-Cool is to cool the brain so as to reduce the metabolic demand. So, cooling is very attractive; when you cool the tissue, it reduces the metabolic demand. And by that, we are hoping to achieve decreased damage during the time that we are delivering evidence-based therapies like intravenous thrombolysis and endovascular thrombectomy. And we hope to add this on as a complementary strategy in addition to the reperfusion therapies. For the trial, this is part of one of the four trials which we have received a grant for, called the Center of Advanced Research from the ICMR. The ICMR is the apex scientific body in India. And so, for this, we are doing this trial in three phases. The first phase is to, of course, build this technology. And we are doing this with our collaborative partners at IIT Kharagpur. The second phase would be to test this in healthy volunteers, and lastly, to kind of test this in acute ischemic stroke patients. What success would look like is first, we need to see whether this technology can be developed well, whether this is effective, and whether this is feasible, this is safe, and well, and how well it can be integrated into the time-critical stroke care pathway.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.